The problem of adherence to therapy in patients with coronary heart disease

Cardiovascular diseases (CVD) occupy the first place in the structure of morbidity, mortality and disability of the population, therefore, the problem of effective treatment of CVD is still one of the most important in modern cardiology.

CV diseases require lifelong therapy, so overcoming poor adherence is relevant in the treatment of patients. Suboptimal adherence is a proven risk factor that decreases the effectiveness of treatment, increases the risk of developing CV complications, as well as worsens the disease outcomes and quality of life. In addition, there is a large number of factors affecting adherence to treatment, which significantly complicates the solution of this problem. Coronary heart disease (CHD) due to high prevalence worldwide is a poorly managed risk factor for CV risk and death. Despite the wide range of available medications, adherence to therapy in CHD patients is extremely low and it is associated with an unfavorable CV prognosis. Prescription of adequate drug treatment improves the clinical condition of CHD patients and decreases the level of CV complications and death. Currently, there is no single strategy for improving adherence to treatment. There is a negative correlation between the level of adherence to therapy and the number of prescribed medications. According to current recommendations, one of the most reasonable ways to solve the problem of poor adherence to pharmacotherapy is prescribing single-pill combinations. The concept of using single-pill combinations is defined as the combination of several drugs contained in a single dosage form. This strategy helps to improve the control of several risk factors at the same time and reduce the risk of CV events. The results of many studies confirm the effectiveness of introducing single-pill combinations in the real clinical practice, since it simplifies the treatment regimen and leads to better CV prognosis by reducing the risk of developing CV complications.

This literature review presents a modern view on the problem of adherence to treatment in CHD patients.

1. World Health Organization; Cardiovascular Diseases (CVDs). Year: 2021

2. Raskaliev R.A., Kalyuta T.Yu., Andriyanova E.A., Fedonnikov A.S. Thinking style and nature of stress experience in patients with coronary artery disease. Russian Journal of Cardiology. 2024;29(11):6137. (In Russ.) https://doi.org/10.15829/1560-4071-2024-6137

3. Vaisman D.Sh., Enina E.N. Сoronary artery disease mortality rates in the Russian Federation and a number of regions: dynamics and structure specifics. Cardiovascular Therapy and Prevention. 2024;23(7):3975. (In Russ.) https://doi.org/10.15829/1728-8800- 2024-3975

4. Wang Y., Li Q., Bi L., et al. Global trends in the burden of ischemic heart disease based on the global burden of disease study 2021: the role of metabolic risk factors. BMC Public Health. 2025;25(1):310. https://doi.org/10.1186/s12889-025-21588-9

5. Aggarwal M., Ornish D., Josephson R., et al. Closing Gaps in Lifestyle Adherence for Secondary Prevention of Coronary Heart Disease. The American journal of cardiology. 2021;145:1-11. https://doi.org/10.1016/j.amjcard.2021.01.005

6. Kuzheleva E.A., Fedyunina V.A., Garganeeva A.A. Adherence to treatment and quality of life of patients with cardiovascular diseases at the outpatient treatment stage of medical care. Eurasian heart journal. 2020;(2):34-40. (In Russ.) https://doi.org/10.38109/2225-1685-2020-2-34-40

7. Chowdhury R., Khan H., Heydon E., et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. European heart journal. 2013;34(38):2940-2948. https://doi.org/10.1093/eurheartj/eht295

8. Solomon M.D., Leong T.K., Levin E., et al. Cumulative Adherence to Secondary Prevention Guidelines and Mortality After Acute Myocardial Infarction. 2020;9(6):e014415. https://doi.org/10.1161/JAHA.119.014415

9. Leslie K.H., McCowan C., Pell J.P. Adherence to cardiovascular medication: a review of systematic reviews. Journal of public health (Oxford, England). 2019;41(1):e84-e94. https://doi.org/10.1093/pubmed/fdy088

10. Larina V.N., Fedorova E.V., Lunev V.I., et al. Non-Adherence to Physician’s Recommendations and Associated Risk Factors in Patients Aged 60 Years and Older. Russian Journal of Geriatric Medicine. 2024;4(20):305–313. (In Russ.) https://doi.org/10.37586/2686-8636-4-2024-305-313

11. World Health Organization. Adherence to long-term therapies: Evidence for action. WHO Library Cataloguing-in-Publication Data, Geneva, WHO. 2003;196. ISBN: 9241545992

12. Ho P.M., Magid D.J., Shetterly S.M., et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. American heart journal. 2008;155(4):772- 9. https://doi.org/10.1016/j.ahj.2007.12.011

13. Pereverzeva K.G., Lukyanov M.M., Martsevich S.Yu., et al. Long-term medication adherence in patients with coronary heart disease and myocardial infarction in comparison with other cardiovascular diseases. Therapy. 2019;1:54-59. (In Russ.) https://doi.org/10.18565/therapy.2019.1.54-59

14. Zagrebelnyi A.V., Martsevich S.Yu., Lukyanov M.M., et al. Quality of lipid-lowering therapy in outpatient practice: RECVAS Register data. Russian Journal of Preventive Medicine. 2016;19(1):9-14. (In Russ.) https://doi.org/10.17116/profmed20161919-14

15. Yusuf S., Islam S., Chow C.K., et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011;378(9798):1231- 43. https://doi.org/10.1016/S0140-6736(11)61215-4

16. Kokozheva M.A., Mardanov B.U., Mamedov M.N. Comparative analysis of pharmacotherapy for patients with coronary artery disease and type 2 diabetes at various healthcare stages. Russian Journal of Cardiology. 2024;29(3):5695. (In Russ.) https://doi.org/10.15829/1560-4071-2024-5695

17. Pedersen E., Primicerio R., Halvorsen K.H., et al. Medication adherence among persons with coronary heart disease and associations with blood pressure and low-density-lipoproteincholesterol. European journal of clinical pharmacology. 2022;78(5):857-867. https://doi.org/10.1007/s00228-022-03276-4

18. Shchinova A.M., Potekhina A.V., Dolgusheva Yu.A., et al. Adherence to therapy after myocardial infarction and methods for its improvement. Journal of Atherosclerosis and Dyslipidemias. 2022;3(48):5-13 (in Russ.) https://doi.org/10.34687/2219-8202.JAD.2022.03.0001

19. Bahit M.C., Korjian S., Daaboul Y., et al. Patient Adherence to Secondary Prevention Therapies After an Acute Coronary Syndrome: A Scoping Review. Clinical therapeutics. 2023;45(11):1119-1126. https://doi.org/10.34687/2219-8202.JAD.2022.03.0001

20. Ho P.M., Spertus J.A., Masoudi F.A., et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Archives of internal medicine. 2006;166(17):1842-1847. https:// doi.org/10.1001/archinte.166.17.1842

21. Khaisheva L.A., Glova S.E., Suroedov V.A., et al. Evaluation of drug therapy and adherence to it in patients after acute coronary syndrome in real clinical practice (results of one year observation). Rational Pharmacotherapy in Cardiology. 2018;14(6):852-857. (In Russ.) https://doi.org/10.20996/1819-6446-2018-14-6-852-857

22. Urbinati S, Olivari Z, Gonzini L, et al. Secondary prevention after acute myocardial infarction: drug adherence, treatment goals, and predictors of health lifestyle habits. The BLITZ-4 Registry. European journal of preventive cardiology. 2015;22(12):1548-1556. https://doi.org/10.1177/2047487314561876

23. Pietrzykowski Ł., Michalski P., Kosobucka A., et al. Medication adherence and its determinants in patients after myocardial infarction. Scientific reports. 2020;10(1):12028. https://doi.org/10.1038/s41598-020-68915-1

24. Crowley M.J., Zullig L.L., Shah B.R., et al. Medication non-adherence after myocardial infarction: an exploration of modifying factors. Journal of general internal medicine. 2015;30(1):83-90. https://doi.org/10.1007/s11606-014-3072-x

25. Naderi S.H., Bestwick J.P., Wald D.S. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. The American journal of medicine. 2012;125(9):882-7.e1. https://doi.org/10.1016/j.amjmed.2011.12.013

26. Gorbunova E.V., Sedykh D.Yu., Maksimov S.A. Psychological and social factors of adherence to treatment in patients with myocardial infarction. Therapeutic Archive. 2018;90(12):34-38. (In Russ.) https://doi.org/10.26442/00403660.2018.12.000006

27. Fitilev S.B., Vozzhaev A.V., Shkrebniova I.I., et al. Electronic medical information and analytical system (EMIAS) as a tool for the new level of understanding and diagnosis of medication adherence in patients with myocardial infarction in primary care practice in Moscow. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2024;(2):16-32. (In Russ.) https://doi.org/10.37489/2588-0519-2024-2-16-32

28. Marselin A., Amalia L., Dinarti L.K. The interventions to improve medication adherence in coronary heart disease patient: A systematic review. Journal of the Saudi Heart Association. 2023;35(4):259-278. https://doi.org/10.37616/2212-5043.1356

29. Rublev V.Yu., Geltser B.I., Sergeyev E.A., et al. Comorbidity of coronary artery disease and its significance in predicting the results of coronary artery bypass grafting. Bulletin of Siberian Medicine. 2022;21(1):152–161. (In Russ.) https://doi.org/10.20538/1682-0363-2022-1-152-161

30. Drapkina O.M., Kontsevaya A.V., Kalinina A.M., et al. Comorbidity of patients with noncommunicable diseases in general practice. Eurasian guidelines. Cardiovascular Therapy and Prevention. 2024;23(3):3996. (In Russ.) https://doi.org/10.15829/1728-8800-2024-3996

31. Joseph P., Roshandel G., Gao P., et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet. 2021;398(10306):1133-1146. https://doi.org/10.1016/S0140-6736(21)01827-4

32. Castellano J.M., Pocock S.J., Bhatt D.L., et al. Polypill Strategy in Secondary Cardiovascular Prevention. The New England journal of medicine. 2022;387(11):967–977. https://doi.org/10.1056/NEJMoa2208275

33. Bertrand M.E., Ferrari R., Remme W.J., et al. Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis. American heart journal. 2015;170(6):1092- 1098. https://doi.org/10.1016/j.ahj.2015.08.018

34. Boytsov S.A., Karpov Yu.A., Burtsev Yu.P., Khomitskaya Yu.V. on behalf of all participants of the STYLE study. The Efficacy of Fixed Combination of Bisoprolol and Perindopril Depending on the Doses Used in Patients with Arterial Hypertension and Stable Coronary Heart Disease in Real Clinical Practice (STYLE Study) Atmosphere. Cardiology News. 2021;1:30-8. (In Russ.) https://doi.org/10.24412/2076-4189-2021-12344

35. Masi S., Kobalava Z., Veronesi C., et al. A Retrospective Observational Real-Word Analysis of the Adherence, Healthcare Resource Consumption and Costs in Patients Treated with Bisoprolol/Perindopril as Single-Pill or Free Combination. Advances in therapy. 2024;41(1):182-197. https://doi.org/10.1007/s12325-023-02707-7

36. Barbarash O.L.. Karpov Yu.A.. Panov A.V., et al. 2024 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2024;29(9):6110. (In Russ.) https://doi.org/10.15829/1560-4071-2024-6110

37. Vrints C., Andreotti F., Koskinas K.C., et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. European heart journal. 2024;45(36):3415-3537. https://doi.org/10.1093/eurheartj/ehae177